Bridgewater Associates LP Has $3.66 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bridgewater Associates LP reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 30.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,861 shares of the company’s stock after selling 3,888 shares during the period. Bridgewater Associates LP’s holdings in IDEXX Laboratories were worth $3,663,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sanctuary Advisors LLC raised its holdings in shares of IDEXX Laboratories by 20.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 3,288 shares of the company’s stock worth $1,661,000 after buying an additional 558 shares in the last quarter. Tidal Investments LLC grew its position in IDEXX Laboratories by 7.6% in the third quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock valued at $3,188,000 after acquiring an additional 444 shares during the period. Franklin Resources Inc. raised its stake in IDEXX Laboratories by 2.5% during the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after acquiring an additional 34,305 shares in the last quarter. American Trust bought a new position in shares of IDEXX Laboratories during the third quarter valued at $757,000. Finally, Oddo BHF Asset Management Sas acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $1,128,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $411.72 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The stock has a market capitalization of $33.37 billion, a P/E ratio of 38.59, a P/E/G ratio of 3.41 and a beta of 1.50. The business has a 50-day moving average price of $423.41 and a two-hundred day moving average price of $431.80.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several analyst reports. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a report on Monday. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $523.75.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.